President & Chief Operating Officer
Jeff is President & Chief Operating Officer (COO) of Apotex. Appointed in 2018, Jeff oversees the day-to-day operations of Apotex, including research and development, manufacturing, packaging and distribution of products across three Lines of Business to more than 115 countries around the globe.
Prior to this role, Jeff was President, Global Generics, the largest line of business at Apotex, where he provided leadership for the Commercial and Strategic Operations and was instrumental in delivering significant growth. A 25-year veteran of Apotex, Jeff has held progressively senior positions within Sales and Marketing since 1993 when he joined the company.
Before joining Apotex, Jeff spent time working in the retail pharmacy sector for Shoppers Drug Mart, Canada’s leading pharmacy chain.
Jeff has been a member of the Association for Accessible Medicines (AAM) Board of Directors since 2012 and served as Chair in 2017. In 2008 he became an Executive Member of the Canadian Generic Pharmaceutical Association’s (CGPA) board. From March 2015-February 2017, he served as Chair of CGPA’s board following three years of service as Vice Chair. Jeff is a former Chair of the US Healthcare Distribution Alliance’s (HDA) knowledge partner, the HDA Research Foundation. He is also the Chair of the Board of Directors for TruLeaf Sustainable Agriculture, Nova Scotia, Canada.
President, Global API
Pere joined Apotex Pharmachem in September 2015 as Vice President and General Manager at the Brantford site. Prior to joining Apotex, Pere spent 18 years with Boehringer Ingelheim Pharma gaining experience in API manufacturing. As President, Global API (GAPI) Pere oversees 6 API manufacturing sites (located in Canada, Mexico, India and China), as well as, working with 3rd party sourcing from over 200 suppliers. Pere also manages the role of R&D on API as a significant importance for developing new molecules to support future launches. GAPI’s mandate strives for excellence in safety, quality and productivity. Pere is a graduate of Universidad de Barcelona with a Ph.D. in Chemical Engineering. He also has a Master in Business Administration from ESADE Business school.
SVP, Global Enablement Operations and Global Chief Information Officer
Shlomo joined Apotex in 2012, and currently has global accountability for our enterprise enabling functions; such as IT, Legal, and Indirect Procurement. Prior to joining Apotex, Shlomo was a Partner at Accenture, where he spent 19 years of his career identifying, qualifying, defining, planning, and successfully delivering large-scale transformation programs at Fortune 500 companies. Shlomo is a Mechanical Engineering alumnus from the University of Toronto; and a graduate of the Institute of Corporate Directors from Rotman School of Management.
CMA, CPA – SVP, Global Finance
Gordon began his career at Apotex in 1989 and rose to Senior Management in 1993. Throughout 2000-2001, he led our company's SAP implementation. Today, he is responsible for managing the financial risk, planning and reporting for the pharmaceutical operations of the Apotex group. This includes consolidating and analyzing financial data to support executive decision-making. Gordon is also responsible for global financial policies, processes and promoting financial governance across the organization.
SVP, Chief Human Resources Officer
Jean-Luc, a French citizen, has brought more than 25 years of diverse experiences in human resources in blue-chip companies such as Mercedes Benz, GE and Sandoz at international levels along with some years as a commercial and marketing leader to his role at Apotex. He is skilled in ensuring talent is well-positioned and recognized, which is critical in delivering leading performance. Since joining Apotex in August 2016, Jean-Luc has led the Human Resources function driving the HR, EHS, and Communication functions while focusing on developing organization, people and talent strategies that aligns with and supports the organization's strategic direction and operational activities. Jean-Luc is an alumni of ESA, ESSEC and Manheim Business schools.
EVP, Global Supply and Technical Operations
Steve brings over 30 years' operations leadership experience to Apotex, including 25 years in leading international pharmaceutical manufacturing and supply organizations. In his current role, Steve is responsible for leading Apotex's global finished dosage manufacturing, supply, engineering and technical operations. This includes production and supply sites in Canada, USA, Europe, and India. Prior to joining Apotex in 2013, Steve had a diverse career in the global Pharmaceutical industry with Teva, Patheon, AstraZeneca and Eli Lilly.
SVP, Global Quality Operations
Johnny began his career in pharmaceuticals in 1982 as an Industrial Microbiologist, later growing to head the compliance and quality operations at several major pharmaceutical manufacturers. Johnny holds a BS in Biology and an MS in Microbiology and brings accomplishments from Duke University, London's British Standards Institute, and Harvard University. Johnny joined Apotex in 2015, and is responsible for the global leadership of the Quality and Compliance Group, ensuring compliance with all health authority regulations and sustained product supply while seamlessly developing and executing strategy grounded in our core values.
SVP, Global Business Transformation & Strategic Planning
In June 2017, Ulrich joined Apotex from Sandoz where he served as Head of Strategy. Prior to Sandoz, Ulrich worked with The Boston Consulting Group and A.T. Kearney as a top management consultant. He has extensive global experience with five years working in China and long assignments in Russia, Ukraine, India, South East Asia, Korea and Japan. Trained as an attorney-at-law in Germany, Ulrich started his career with the German specialty chemicals company WACKER Chemie, working in strategic marketing, business development and key account sales. In his capacity, Ulrich has global responsibility for the Apotex Strategy and Strategic Planning processes. He will drive a number of cross-enterprise initiatives around Growth and Cost & Profitability, GBS being one of these.